Fora Capital, LLC Zai Lab LTD Transaction History

Fora Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$27.77 - $64.4 $127,075 - $294,694	-4,576 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$54.9 - $105.21 $136,097 - $260,815	-2,479 Reduced 35.14%	4,576 $288,000
Q3 2021 Nov 15, 2021	BUY	$105.0 - $178.37 $649,110 - $1.1 Million	6,182 Added 708.13%	7,055 $744,000
Q2 2021 Aug 16, 2021	SELL	$125.11 - $180.0 $404,355 - $581,760	-3,232 Reduced 78.73%	873 $155 Million
Q1 2021 May 17, 2021	BUY	$126.27 - $191.71 $497,377 - $755,145	3,939 Added 2372.89%	4,105 $548 Million
Q4 2020 Feb 12, 2021	BUY	$81.94 - $135.34 $13,602 - $22,466	166 New	166 $22,000
Q3 2020 Nov 13, 2020	SELL	$73.3 - $89.48 $234,926 - $286,783	-3,205 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$48.82 - $82.53 $130,349 - $220,355	2,670 Added 499.07%	3,205 $263 Million
Q1 2020 May 15, 2020	SELL	$39.1 - $62.9 $48,444 - $77,933	-1,239 Reduced 69.84%	535 $27,000
Q4 2019 Feb 14, 2020	BUY	$29.79 - $43.06 $52,847 - $76,388	1,774 New	1,774 $73,000

123

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.55B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.